Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sergio Fazio

Showing results (51-60 of 284) with videos related to

Pageof 29
Sort By:
Circulation Research|May 12, 2018
PCSK9: From Basic Science Discoveries to Clinical TrialsMichael D Shapiro, Hagai Tavori, Sergio Fazio
Journal of the American College of Cardiology|March 18, 2014
The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapiesAllan D Sniderman, Sotirios Tsimikas, Sergio Fazio
Nature Reviews. Nephrology|November 25, 2010
Atherosclerosis in chronic kidney disease: the role of macrophagesValentina Kon, MacRae F Linton, Sergio Fazio
Current Opinion in Nephrology and Hypertension|March 9, 2013
Importance of high-density lipoprotein quality: evidence from chronic kidney diseaseValentina Kon, T Alp Ikizler, Sergio Fazio
Current Atherosclerosis Reports|February 26, 2015
Targeting PCSK9 for therapeutic gainsMichael D Shapiro, Sergio Fazio, Hagai Tavori
Pediatric Annals|February 4, 2012
Dyslipidemias in childrenJessica Sparks Lilley, MacRae F Linton, Sergio Fazio
Arteriosclerosis, Thrombosis, and Vascular Biology|June 5, 2004
Proatherogenic role for NK cells revealedMacRae F Linton, Amy S Major, Sergio Fazio
Journal of Clinical Medicine|August 29, 2024
Correction: Ferri et al. Low-Density Lipoprotein Cholesterol-Lowering Drugs: A Narrative Review. <i>J. Clin. Med.</i> 2024, <i>13</i>, 943Nicola Ferri, Massimiliano Ruscica, Sergio Fazio, et al.
Journal of Clinical Medicine|February 24, 2024
Low-Density Lipoprotein Cholesterol-Lowering Drugs: A Narrative ReviewNicola Ferri, Massimiliano Ruscica, Sergio Fazio, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|January 1, 2005
ACAT inhibition: bad for macrophages, good for smooth muscle cells?Sergio Fazio, Dwayne E Dove, MacRae F Linton
Pageof 29

Showing results (51-60 of 284) with videos related to

Sort By:
Pageof 29
Circulation Research|May 12, 2018
PCSK9: From Basic Science Discoveries to Clinical TrialsMichael D Shapiro, Hagai Tavori, Sergio Fazio
Journal of the American College of Cardiology|March 18, 2014
The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapiesAllan D Sniderman, Sotirios Tsimikas, Sergio Fazio
Nature Reviews. Nephrology|November 25, 2010
Atherosclerosis in chronic kidney disease: the role of macrophagesValentina Kon, MacRae F Linton, Sergio Fazio
Current Opinion in Nephrology and Hypertension|March 9, 2013
Importance of high-density lipoprotein quality: evidence from chronic kidney diseaseValentina Kon, T Alp Ikizler, Sergio Fazio
Current Atherosclerosis Reports|February 26, 2015
Targeting PCSK9 for therapeutic gainsMichael D Shapiro, Sergio Fazio, Hagai Tavori
Pediatric Annals|February 4, 2012
Dyslipidemias in childrenJessica Sparks Lilley, MacRae F Linton, Sergio Fazio
Arteriosclerosis, Thrombosis, and Vascular Biology|June 5, 2004
Proatherogenic role for NK cells revealedMacRae F Linton, Amy S Major, Sergio Fazio
Journal of Clinical Medicine|August 29, 2024
Correction: Ferri et al. Low-Density Lipoprotein Cholesterol-Lowering Drugs: A Narrative Review. <i>J. Clin. Med.</i> 2024, <i>13</i>, 943Nicola Ferri, Massimiliano Ruscica, Sergio Fazio, et al.
Journal of Clinical Medicine|February 24, 2024
Low-Density Lipoprotein Cholesterol-Lowering Drugs: A Narrative ReviewNicola Ferri, Massimiliano Ruscica, Sergio Fazio, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|January 1, 2005
ACAT inhibition: bad for macrophages, good for smooth muscle cells?Sergio Fazio, Dwayne E Dove, MacRae F Linton
Pageof 29